The studies of the molecular mechanism of inherited susceptibility to cancer are significantly aided by the identification and analysis of predisposing genes from familial cancer syndromes such as retinoblastoma, Wilms'Tumors, Neurofibromatosis Type I, and Familial Polyposis Coli. The tumor suppressor gene p53 has been shown to frequently altered in a wide variety of sporatic tumors. In these instances, one allele of p53 has been lost and the remaining allele has acquired a somatic mutation. The identification of a germ-line p53 mutation in cancer-prone families with Li-Fraumeni syndrome (LFS) has introduced a new role for p53, i.e., a role in genetic susceptibility to cancer. Our recent studies show that the normal skin fibroblast (NSFs) cells derived from individuals in the cancer- prone family express low levels of both wild-type (wt) and mutant (mt) p 53 protein at levels comparable to that of the wt p53 detected in normal cells. Furthermore, tumors arising from two germ-layers in four different individuals in this family exhibited the loss of the wt p53 allele and the retention of the mt allele. We have also known that many of the mutations in p53 found in LFS families appear to have a transdominant effect over the wt p53 in in vitro assays. To understand the role of germ-line p53 mutations in genetic predisposition and tumorigenesis, we propose to analyze the biological and biochemical characteristics of mt p53 found in this cancer-prone family with LFS. Therefore, we will examine the SV40 T Ag, MDM-2 and sequence specific DNA binding properties of p53 in these NSFs, and evaluate the effect of this wt/mt phenotype on cell cycle progression and apoptosis. Such analysis will provide information on the effects of mt p53 on the functions of wt p53 in a heterozygous situation. We will extend these studies to other LFS families in order to understand the broad implications of these findings for inherited p53 mutations. Since the p53 protein exhibits the properties of a transcription factor and binds to specific DNA sequences in vitro, the family NSFs with endogenous expression of both mt and wt p53 provide a good experimental system with which to identify target genes modulated by mutation in p53. The status of such genes will be evaluated by the analysis of either the expression of previously identified cell growth associated genes or the expression of genes which are differentially regulated in family NSFs (wt/mt). Thus, the experiments proposed in this application should serve not only to increase our understanding of the functional implications of mt p53 in predisposition, tumor formation and progression in cancer-prone families with LFS but should also yield information relevant to the function of p53 in tumorigenesis in general.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA045158-13S1
Application #
2693700
Study Section
Experimental Virology Study Section (EVR)
Program Officer
Cole, John S
Project Start
1986-09-01
Project End
1999-11-30
Budget Start
1997-12-01
Budget End
1999-11-30
Support Year
13
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Georgetown University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Xu, Liang; Huang, Cheng-Cheng; Huang, Weiqun et al. (2002) Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 1:337-46
Sherif, Z A; Nakai, S; Pirollo, K F et al. (2001) Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther 8:771-82
Xu, L; Pirollo, K F; Chang, E H (2001) Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release 74:115-28
Xu, L; Tang, W H; Huang, C C et al. (2001) Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 7:723-34
Pirollo, K F; Bouker, K B; Chang, E H (2000) Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 11:419-32
Xu, L; Pirollo, K F; Tang, W H et al. (1999) Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther 10:2941-52
Pirollo, K F; Hao, Z; Rait, A et al. (1997) Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem Biophys Res Commun 230:196-201
Xu, L; Pirollo, K F; Chang, E H (1997) Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum Gene Ther 8:467-75
Pirollo, K F; Hao, Z; Rait, A et al. (1997) p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 14:1735-46
Srivastava, S; Wang, S; Tong, Y A et al. (1993) Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53. Oncogene 8:2449-56

Showing the most recent 10 out of 16 publications